A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson’s Disease
Cells · 2025
DOI: 10.3390/cells14050338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Andrea Spinaci und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy. Hauptthemen laut MEDLINE: Adenosine A2 Receptor Antagonists, Parkinson Disease, Receptor, Adenosine A2A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MURST (Italian Ministry of Education, Universities and Research), Università di Camerino, FIRB of MURST (Italian Ministry of Education, Universities, and Research.
Abstract (Originalsprache)
Parkinson’s disease (PD) represents a growing challenge to global health, as it involves millions of people. The high grade of disability is due to the loss of dopaminergic neuron activity, and levodopa is the gold-standard therapy used to restore dopamine in the dopamine-denervated regions. Another therapeutic approach is the use of A2A adenosine receptor antagonists and, among them, istradefylline is the only one currently approved for therapy in association with levodopa. In this work, we synthesized A2A adenosine receptor antagonists represented by 9-ethyl-2,8-disubstituted adenine derivatives, which were tested at human adenosine receptors in binding and functional assays. These compounds showed A2A adenosine receptor-binding affinities in the low nanomolar range and 1, 4, and 5 exhibited good potency in the functional assays. Hence, they were evaluated in in vivo rat models of PD, where they were demonstrated to revert haloperidol-induced catalepsy and potentiate levodopa-induced contralateral rotations in 6-hydroxydopamine-lesioned rats. The most potent derivative, 4, was then evaluated in the tacrine model, where it reduced the tremulous jaw movements, therefore demonstrating an action on parkinsonian tremor. These data revealed 8-ethoxy-2-phenethoxy-9-ethyladenine (4) as an A2A adenosine receptor antagonist endowed with antiparkinsonian effects and as a good candidate to treat the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.
- Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Str. 9, D-97078 Würzburg, Germany.
- Department of Biomedical Sciences, Section of Neuroscience, University of Cagliari, Cittadella Universitaria, SP 8, Km 0.700, I-09042 Monserrato, Italy.
- Neuroscience Institute, National Research Council of Italy (CNR), Cagliari Cittadella Universitaria, SP 8, Km 0.700, I-09042 Monserrato, Italy.
ORCID-Profile: Andrea Spinaci, Michela Buccioni, Diego Dal Ben, Beatrice Francucci, Nicola Simola, Annalisa Pinna, Rosaria Volpini, Catia Lambertucci
Förderung
- MURST (Italian Ministry of Education, Universities and Research)
- Università di Camerino
- FIRB of MURST (Italian Ministry of Education, Universities, and Research
- Fondo di Ricerca di Ateneo, University of Camerino
Zitieren
APA
Spinaci, A., Buccioni, M., Dal Ben, D., Francucci, B., Klotz, K. N., Marucci, G., Simola, N., Morelli, M., Pinna, A., Volpini, R., & Lambertucci, C. (2025). A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson’s Disease. Cells. https://doi.org/10.3390/cells14050338
Vancouver
Spinaci A, Buccioni M, Dal Ben D, Francucci B, Klotz KN, Marucci G, et al. A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson’s Disease. Cells. 2025. doi:10.3390/cells14050338
BibTeX
@article{Spinaci2025,
author = {Spinaci, Andrea and Buccioni, Michela and Dal Ben, Diego and Francucci, Beatrice and Klotz, Karl-Norbert and Marucci, Gabriella and Simola, Nicola and Morelli, Micaela and Pinna, Annalisa and Volpini, Rosaria and Lambertucci, Catia},
title = {A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson’s Disease},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14050338}
}
EUVIMED